Literature DB >> 22239286

Interaction of I50V mutant and I50L/A71V double mutant HIV-protease with inhibitor TMC114 (darunavir): molecular dynamics simulation and binding free energy studies.

Biswa Ranjan Meher1, Yixuan Wang.   

Abstract

In the present work, the binding of inhibitor TMC114 (darunavir) to wild-type (WT), single (I50V) as well as double (I50L/A71V) mutant HIV-proteases (HIV-pr) was investigated with all-atom molecular dynamics (MD) simulations as well as molecular mechanic-Poisson-Boltzmann surface area (MM-PBSA) calculation. For both the apo and complexed HIV-pr, many intriguing effects due to double mutant, I50L/A71V, are observed. For example, the flap-flap distance and the distance from the active site to the flap residues in the apo I50L/A71V-HIV-pr are smaller than those of WT- and I50V-HIV-pr, probably making the active site smaller in volume and closer movement of flaps. For the complexed HIV-pr with TMC114, the double mutant I50L/A71V shows a less curling of the flap tips and less flexibility than WT and the single mutant I50V. As for the other previous studies, the present results also show that the single mutant I50V decreases the binding affinity of I50V-HIV-pr to TMC, resulting in a drug resistance; whereas the double mutant I50L/A71V increases the binding affinity, and as a result of the stronger binding, the I50L/A71V may be well adapted by the TMC114. The energy decomposition analysis suggests that the increase of the binding for the double mutant I50L/A71V-HIV-pr can be mainly attributed to the increase in electrostatic energy by -5.52 kacl/mol and van der Waals by -0.42 kcal/mol, which are canceled out in part by the increase of polar solvation energy of 1.99 kcal/mol. The I50L/A71V mutant directly increases the binding affinity by approximately -0.88 (Ile50 to Leu50) and -0.90 (Ile50' to Leu50') kcal/mol, accounting 45% for the total gain of the binding affinity. Besides the direct effects from the residues Leu50 and Leu50', the residue Gly49' increases the binding affinity of I50L/A71V-HIV-pr to the inhibitor by -0.74 kcal/mol, to which the electrostatic interaction of Leu50's backbone contributes by -1.23 kcal/mol. Another two residues Ile84 and Ile47' also increase the binding affinity by -0.22 and -0.29 kcal/mol, respectively, which can be mainly attributed to van der Waals terms (ΔT(vdw) = -0.21 and -0.39 kcal/mol).

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22239286      PMCID: PMC3288396          DOI: 10.1021/jp2074804

Source DB:  PubMed          Journal:  J Phys Chem B        ISSN: 1520-5207            Impact factor:   2.991


  44 in total

1.  Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes.

Authors:  Holger Gohlke; Christina Kiel; David A Case
Journal:  J Mol Biol       Date:  2003-07-18       Impact factor: 5.469

2.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

3.  HIV-1 protease mutations and inhibitor modifications monitored on a series of complexes. Structural basis for the effect of the A71V mutation on the active site.

Authors:  Tereza Skalova; Jan Dohnalek; Jarmila Duskova; Hana Petrokova; Martin Hradílek; Milan Soucek; Jan Konvalinka; Jindrich Hasek
Journal:  J Med Chem       Date:  2006-09-21       Impact factor: 7.446

4.  Comparison of multiple Amber force fields and development of improved protein backbone parameters.

Authors:  Viktor Hornak; Robert Abel; Asim Okur; Bentley Strockbine; Adrian Roitberg; Carlos Simmerling
Journal:  Proteins       Date:  2006-11-15

5.  Quantum and molecular dynamics study for binding of macrocyclic inhibitors to human alpha-thrombin.

Authors:  Emilia L Wu; Ye Mei; KeLi Han; John Z H Zhang
Journal:  Biophys J       Date:  2007-03-23       Impact factor: 4.033

6.  Characterization of domain-peptide interaction interface: a case study on the amphiphysin-1 SH3 domain.

Authors:  Tingjun Hou; Wei Zhang; David A Case; Wei Wang
Journal:  J Mol Biol       Date:  2008-01-03       Impact factor: 5.469

7.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA.

Authors:  J Wang; P Morin; W Wang; P A Kollman
Journal:  J Am Chem Soc       Date:  2001-06-06       Impact factor: 15.419

8.  Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance.

Authors:  W R Scott; C A Schiffer
Journal:  Structure       Date:  2000-12-15       Impact factor: 5.006

9.  Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments.

Authors:  Thomas D Wu; Celia A Schiffer; Matthew J Gonzales; Jonathan Taylor; Rami Kantor; Sunwen Chou; Dennis Israelski; Andrew R Zolopa; W Jeffrey Fessel; Robert W Shafer
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

10.  Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272.

Authors:  Y X Wang; D I Freedberg; T Yamazaki; P T Wingfield; S J Stahl; J D Kaufman; Y Kiso; D A Torchia
Journal:  Biochemistry       Date:  1996-08-06       Impact factor: 3.162

View more
  26 in total

1.  A computational analysis of binding modes and conformation changes of MDM2 induced by p53 and inhibitor bindings.

Authors:  Jianzhong Chen; Jinan Wang; Weiliang Zhu; Guohui Li
Journal:  J Comput Aided Mol Des       Date:  2013-11-22       Impact factor: 3.686

2.  Picomolar to Micromolar: Elucidating the Role of Distal Mutations in HIV-1 Protease in Conferring Drug Resistance.

Authors:  Mina Henes; Gordon J Lockbaum; Klajdi Kosovrasti; Florian Leidner; Gily S Nachum; Ellen A Nalivaika; Sook-Kyung Lee; Ean Spielvogel; Shuntai Zhou; Ronald Swanstrom; Daniel N A Bolon; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  ACS Chem Biol       Date:  2019-08-13       Impact factor: 5.100

3.  Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis.

Authors:  Konda Reddy Karnati; Yixuan Wang
Journal:  J Mol Graph Model       Date:  2019-07-18       Impact factor: 2.518

4.  Exploring the drug resistance of V32I and M46L mutant HIV-1 protease to inhibitor TMC114: flap dynamics and binding mechanism.

Authors:  Biswa Ranjan Meher; Yixuan Wang
Journal:  J Mol Graph Model       Date:  2014-12-05       Impact factor: 2.518

5.  Binding of single walled carbon nanotube to WT and mutant HIV-1 proteases: analysis of flap dynamics and binding mechanism.

Authors:  Biswa Ranjan Meher; Yixuan Wang
Journal:  J Mol Graph Model       Date:  2012-10-13       Impact factor: 2.518

6.  Elucidating the Interdependence of Drug Resistance from Combinations of Mutations.

Authors:  Debra A Ragland; Troy W Whitfield; Sook-Kyung Lee; Ronald Swanstrom; Konstantin B Zeldovich; Nese Kurt-Yilmaz; Celia A Schiffer
Journal:  J Chem Theory Comput       Date:  2017-10-09       Impact factor: 6.006

Review 7.  Sequence, Structural Analysis and Metrics to Define the Unique Dynamic Features of the Flap Regions Among Aspartic Proteases.

Authors:  Lara McGillewie; Muthusamy Ramesh; Mahmoud E Soliman
Journal:  Protein J       Date:  2017-10       Impact factor: 2.371

8.  Molecular Determinants of Epistasis in HIV-1 Protease: Elucidating the Interdependence of L89V and L90M Mutations in Resistance.

Authors:  Mina Henes; Klajdi Kosovrasti; Gordon J Lockbaum; Florian Leidner; Gily S Nachum; Ellen A Nalivaika; Daniel N A Bolon; Nese Kurt Yilmaz; Celia A Schiffer; Troy W Whitfield
Journal:  Biochemistry       Date:  2019-08-19       Impact factor: 3.162

9.  Structural Adaptation of Darunavir Analogues against Primary Mutations in HIV-1 Protease.

Authors:  Gordon J Lockbaum; Florian Leidner; Linah N Rusere; Mina Henes; Klajdi Kosovrasti; Gily S Nachum; Ellen A Nalivaika; Akbar Ali; Nese Kurt Yilmaz; Celia A Schiffer
Journal:  ACS Infect Dis       Date:  2018-12-31       Impact factor: 5.084

10.  Investigation on the mechanism for the binding and drug resistance of wild type and mutations of G86 residue in HIV-1 protease complexed with Darunavir by molecular dynamic simulation and free energy calculation.

Authors:  Dan Li; Ying Zhang; Run-Ning Zhao; Song Fan; Ju-Guang Han
Journal:  J Mol Model       Date:  2014-02-14       Impact factor: 1.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.